ESMO-话题@MedSci

#ESMO#

214篇内容 | 5241人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1281055, encodeId=d53b1281055cb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2020年ESMO指南: 胃肠胰神经内分泌肿瘤的诊治和随访, objectType=article, longId=215753, objectId=f337215e53c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f337215e53c3, replyNumber=0, likeNumber=75, createdTime=2021-08-16, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f337215e53c3, moduleTitle=2020年ESMO指南: 胃肠胰神经内分泌肿瘤的诊治和随访, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f337215e53c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281054, encodeId=37b61281054ba, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：肿瘤突变负荷可预测口腔鳞状细胞癌患者预后, objectType=article, longId=212770, objectId=6d66212e701d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d66212e701d, replyNumber=0, likeNumber=87, createdTime=2021-06-17, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d66212e701d, moduleTitle=ESMO Open：肿瘤突变负荷可预测口腔鳞状细胞癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d66212e701d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281053, encodeId=61aa12810532a, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：晚期肉瘤样肾细胞癌采用avelumab联合阿西替尼 vs 舒尼替尼治疗的疗效, objectType=article, longId=210657, objectId=6acc21065ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6acc21065ed0, replyNumber=0, likeNumber=104, createdTime=2021-05-01, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6acc21065ed0, moduleTitle=ESMO Open：晚期肉瘤样肾细胞癌采用avelumab联合阿西替尼 vs 舒尼替尼治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6acc21065ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281052, encodeId=ac88128105216, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：阿西替尼治疗肾细胞癌有害无益？, objectType=article, longId=210607, objectId=e78121060ee1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e78121060ee1, replyNumber=0, likeNumber=112, createdTime=2021-04-30, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e78121060ee1, moduleTitle=ESMO Open：阿西替尼治疗肾细胞癌有害无益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e78121060ee1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281051, encodeId=c4771281051d4, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：健康相关生活质量有助于预测卵巢癌患者的短期死亡风险！, objectType=article, longId=209635, objectId=20a620963560, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20a620963560, replyNumber=0, likeNumber=76, createdTime=2021-04-08, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20a620963560, moduleTitle=ESMO Open：健康相关生活质量有助于预测卵巢癌患者的短期死亡风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20a620963560)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281050, encodeId=1fba128105012, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：抗PD-(L)1抗体治疗转移性尿路上皮癌的预后, objectType=article, longId=208783, objectId=b41c208e8335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41c208e8335, replyNumber=0, likeNumber=78, createdTime=2021-03-22, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41c208e8335, moduleTitle=ESMO Open：抗PD-(L)1抗体治疗转移性尿路上皮癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41c208e8335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281049, encodeId=a0b612810495e, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：西地尼布联合化疗治疗复发性卵巢癌的3期试验结果, objectType=article, longId=207454, objectId=c0a120e454b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0a120e454b7, replyNumber=0, likeNumber=90, createdTime=2021-02-24, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0a120e454b7, moduleTitle=ESMO Open：西地尼布联合化疗治疗复发性卵巢癌的3期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0a120e454b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281048, encodeId=bdbc1281048b9, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：老年癌症患者采用免疫抑制剂治疗的副作用风险会更高吗？, objectType=article, longId=206570, objectId=fa272065e0f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa272065e0f2, replyNumber=0, likeNumber=83, createdTime=2021-02-03, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa272065e0f2, moduleTitle=ESMO Open：老年癌症患者采用免疫抑制剂治疗的副作用风险会更高吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa272065e0f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281047, encodeId=4975128104e14, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：免疫检查点抑制剂治疗可降低继发第二原发性癌的发病率, objectType=article, longId=206567, objectId=834320656ebd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=834320656ebd, replyNumber=0, likeNumber=62, createdTime=2021-02-03, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=834320656ebd, moduleTitle=ESMO Open：免疫检查点抑制剂治疗可降低继发第二原发性癌的发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=834320656ebd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281046, encodeId=657d1281046fe, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open | 泰莱生物联合发表基于多组学研究方法的肝癌诊断及预后成果, objectType=article, longId=206392, objectId=6c97206392fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c97206392fd, replyNumber=0, likeNumber=98, createdTime=2021-01-31, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c97206392fd, moduleTitle=ESMO Open | 泰莱生物联合发表基于多组学研究方法的肝癌诊断及预后成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c97206392fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281045, encodeId=b7f01281045dc, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=Nat Commun：基于深度学习和形态学的衰老评分系统（Deep-SeSMo）：抗衰老药物筛选的重要工具, objectType=article, longId=205964, objectId=941720596414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941720596414, replyNumber=0, likeNumber=81, createdTime=2021-01-22, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941720596414, moduleTitle=Nat Commun：基于深度学习和形态学的衰老评分系统（Deep-SeSMo）：抗衰老药物筛选的重要工具, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941720596414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281044, encodeId=a244128104435, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率, objectType=article, longId=205519, objectId=bf4a2055190b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf4a2055190b, replyNumber=0, likeNumber=90, createdTime=2021-01-10, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf4a2055190b, moduleTitle=ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf4a2055190b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281043, encodeId=797f1281043de, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO：50%晚期NSCLC患者可获长达4年生存期度伐利尤单抗治疗显优异生存获益, objectType=article, longId=201226, objectId=f204201226fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f204201226fd, replyNumber=0, likeNumber=71, createdTime=2020-09-27, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f204201226fd, moduleTitle=ESMO：50%晚期NSCLC患者可获长达4年生存期度伐利尤单抗治疗显优异生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f204201226fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281042, encodeId=164d128104291, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=中国妇瘤专家携卵巢癌研究新进展登陆ESMO，患者有了新治疗标准, objectType=article, longId=201193, objectId=7ada2011933c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ada2011933c, replyNumber=0, likeNumber=97, createdTime=2020-09-26, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ada2011933c, moduleTitle=中国妇瘤专家携卵巢癌研究新进展登陆ESMO，患者有了新治疗标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ada2011933c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281041, encodeId=e3b1128104145, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=闪耀ESMO！礼来阿贝西利(abemaciclib)显著降低HR+，HER2-高危早期乳腺癌患者复发风险达25%, objectType=article, longId=201086, objectId=83de20108654, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83de20108654, replyNumber=0, likeNumber=70, createdTime=2020-09-24, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83de20108654, moduleTitle=闪耀ESMO！礼来阿贝西利(abemaciclib)显著降低HR+，HER2-高危早期乳腺癌患者复发风险达25%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83de20108654)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281040, encodeId=69ac1281040a2, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=基石药业舒格利单抗一线数据亮相ESMO，胃癌、食管鳞癌再迎新突破, objectType=article, longId=201028, objectId=cf56201028f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf56201028f4, replyNumber=0, likeNumber=69, createdTime=2020-09-23, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf56201028f4, moduleTitle=基石药业舒格利单抗一线数据亮相ESMO，胃癌、食管鳞癌再迎新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf56201028f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281039, encodeId=5cea1281039bc, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=中国患者数据来了！本土卵巢癌PARP抑制剂3期临床研究成果闪耀ESMO, objectType=article, longId=200959, objectId=4aa820095905, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aa820095905, replyNumber=0, likeNumber=129, createdTime=2020-09-21, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aa820095905, moduleTitle=中国患者数据来了！本土卵巢癌PARP抑制剂3期临床研究成果闪耀ESMO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aa820095905)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281038, encodeId=df811281038cb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2020 ESMO：英飞凡治疗III期非小细胞肺癌迎来重大突破，约50％的患者获得了长达四年的生存期, objectType=article, longId=200935, objectId=015b2009357f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015b2009357f, replyNumber=0, likeNumber=64, createdTime=2020-09-21, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015b2009357f, moduleTitle=2020 ESMO：英飞凡治疗III期非小细胞肺癌迎来重大突破，约50％的患者获得了长达四年的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015b2009357f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281037, encodeId=49fd128103e6f, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2020：EPI-7386治疗前列腺癌的临床前数据，取得积极结果, objectType=article, longId=200900, objectId=6e0d20090012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e0d20090012, replyNumber=0, likeNumber=74, createdTime=2020-09-20, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e0d20090012, moduleTitle=ESMO 2020：EPI-7386治疗前列腺癌的临床前数据，取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e0d20090012)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281036, encodeId=ee7b128103667, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2020：抗体-药物偶联物Tisotumab vedotin治疗复发宫颈癌取得积极进展, objectType=article, longId=199963, objectId=5ce5199963fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ce5199963fc, replyNumber=0, likeNumber=65, createdTime=2020-08-29, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ce5199963fc, moduleTitle=ESMO 2020：抗体-药物偶联物Tisotumab vedotin治疗复发宫颈癌取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ce5199963fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ESMO

2020-05-29

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2020年ESMO指南: 胃肠胰神经内分泌肿瘤的诊治和随访

2021-08-16

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：肿瘤突变负荷可预测口腔鳞状细胞癌患者预后

2021-06-17

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：晚期肉瘤样肾细胞癌采用avelumab联合阿西替尼 vs 舒尼替尼治疗的疗效

2021-05-01

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：阿西替尼治疗肾细胞癌有害无益？

2021-04-30

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：健康相关生活质量有助于预测卵巢癌患者的短期死亡风险！

2021-04-08

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：抗PD-(L)1抗体治疗转移性尿路上皮癌的预后

2021-03-22

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：西地尼布联合化疗治疗复发性卵巢癌的3期试验结果

2021-02-24

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：老年癌症患者采用免疫抑制剂治疗的副作用风险会更高吗？

2021-02-03

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：免疫检查点抑制剂治疗可降低继发第二原发性癌的发病率

2021-02-03

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open | 泰莱生物联合发表基于多组学研究方法的肝癌诊断及预后成果

2021-01-31

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

Nat Commun：基于深度学习和形态学的衰老评分系统（Deep-SeSMo）：抗衰老药物筛选的重要工具

2021-01-22

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open：致病性BRCA1/2胚系突变在胰腺癌患者中的发生率

2021-01-10

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

ESMO：50%晚期NSCLC患者可获长达4年生存期度伐利尤单抗治疗显优异生存获益

2020-09-27

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

中国妇瘤专家携卵巢癌研究新进展登陆ESMO，患者有了新治疗标准

2020-09-26

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

闪耀ESMO！礼来阿贝西利(abemaciclib)显著降低HR+，HER2-高危早期乳腺癌患者复发风险达25%

2020-09-24

智慧医人 (审核中...)

前往app查看评论内容

#ESMO#

基石药业舒格利单抗一线数据亮相ESMO，胃癌、食管鳞癌再迎新突破

2020-09-23

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

中国患者数据来了！本土卵巢癌PARP抑制剂3期临床研究成果闪耀ESMO

2020-09-21

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

2020 ESMO：英飞凡治疗III期非小细胞肺癌迎来重大突破，约50％的患者获得了长达四年的生存期

2020-09-21

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2020：EPI-7386治疗前列腺癌的临床前数据，取得积极结果

2020-09-20

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2020：抗体-药物偶联物Tisotumab vedotin治疗复发宫颈癌取得积极进展

2020-08-29

科室
- - 订阅+
  - 更多科室
工具
服务